Press Releases

Date Title
November 22, 2023 Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference
November 20, 2023 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET
November 13, 2023 Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023
October 13, 2023 Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline
September 17, 2023 Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference
September 7, 2023 Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023
August 31, 2023 Enanta Pharmaceuticals to Participate in Investor Conferences in September
August 7, 2023 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET
July 31, 2023 Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023
June 20, 2023 Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
Displaying 1 - 10 of 28